Drug intelligence / Profile preview

YOLT-102

Development stage: Preclinical
Lead developer: YolTech Therapeutics
Modality: Vaccines & Immunotherapeutics, Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

YOLT-102 is an investigational gene-editing therapeutic developed by Yoltech Therapeutics for the treatment of atherosclerosis. The drug is currently in preclinical development and is part of Yoltech's pipeline focused on cardiovascular and metabolic diseases. While specific details about its mechanism of action are not publicly disclosed, Yoltech specializes in mRNA drugs and gene editing therapies, often utilizing advanced technologies such as CRISPR, base editing, and lipid nanoparticle (LNP) delivery systems. The company aims to address genetic diseases through innovative in vivo gene-editing approaches[1][3][4].

Beyond the preview

Go deeper on YOLT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YOLT-102.

Explore the full profile